SCHEMBL2772403

SCHEMBL2772403

O=CCc1ccc(O)c([N+](=O)[O-])c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH5A1 P51649 1/20 0.59
ABAT P80404 1/20 0.59
MAPT P10636 4/20 0.57
NPSR1 Q6W5P4 1/20 0.57
POLB P06746 1/20 0.55
MAPK1 P28482 2/20 0.55
ALDH1A1 P00352 2/20 0.55
TP53 P04637 1/20 0.55
HPGD P15428 1/20 0.55
TSHR P16473 1/20 0.55
SMN1; SMN2 Q16637 1/20 0.55
GPR35 Q9HC97 1/20 0.55
L3MBTL1 Q9Y468 2/20 0.53
ALOX15 P16050 1/20 0.53
HSD17B10 Q99714 1/20 0.53
CA12 O43570 1/20 0.50
CA1 P00915 1/20 0.50
CA2 P00918 1/20 0.50
CA9 Q16790 1/20 0.50
DBH P09172 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8733637 0.86 XDH (0.58) ALDH5A1ABATMAPTNPSR1POLB
SCHEMBL30477507 0.83 SNCA (0.62) ALDH5A1ABATMAPTNPSR1POLB
SCHEMBL69585 0.83 SNCA (0.62) ALDH5A1ABATMAPTNPSR1POLB
SCHEMBL11002820 0.83 MAPK1 (0.60) ALDH5A1ABATMAPTNPSR1POLB
SCHEMBL6947527 0.83 TSHR (0.48) ALDH5A1ABATMAPTNPSR1POLB
SCHEMBL1736272 0.81 POLB (0.62) ALDH5A1ABATMAPTNPSR1POLB
SCHEMBL1025776 0.80 POLB (0.56) ALDH5A1ABATMAPTNPSR1POLB
SCHEMBL3529585 0.80 POLB (0.56) ALDH5A1ABATMAPTNPSR1POLB
SCHEMBL346032 0.80 POLB (0.65) ALDH5A1ABATMAPTNPSR1POLB
SCHEMBL532173 0.80 POLB (0.56) ALDH5A1ABATMAPTNPSR1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9926332-B2 Dihydro-oxazinobenzodiazepine compounds, a process for their preparation and pharmaceutical compositions containing them EGIS GYOGYSZERGYAR ZRT. (HU) 2018-03-27 US disclosed
EP-2970114-A1 IDO INHIBITORS Bristol-Myers Squibb Company (US) 2016-01-20 EP disclosed
WO-2014150646-A1 IDO INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2014-09-25 WO disclosed
WO-2010111626-A2 POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-30 WO disclosed
EP-2035004-A1 PHENYL SUBSTITUTED PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS POSSESSING BETA AGONIST ACTIVITY Parion Sciences, Inc. (US) 2009-03-18 EP disclosed
WO-2007146869-A1 PHENYL SUBSTITUTED PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS POSSESSING BETA AGONIST ACTIVITY PARION SCIENCES, INC. (US) 2007-12-21 WO disclosed
WO-2007146867-A2 ALIPHATIC PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS WITH BETA AGONIST ACTIVITY PARION SCIENCES INC. (US) 2007-12-21 WO disclosed
EP-1677783-A2 FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE Nicholas Piramal India Limited (IN) 2006-07-12 EP disclosed
WO-2005035495-A2 FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE NICHOLAS PIRAMAL INDIA LIMITED (IN) 2005-04-21 WO disclosed
WO-1997037646-A1 CATECHOLAMINE SURROGATES USEFUL AS β3 AGONISTS BRISTOL-MYERS SQUIBB COMPANY (US) 1997-10-16 WO disclosed
EP-0772585-A1 ARYLOXY AND ARYLTHIOPROPANOLAMINE DERIVATIVES USEFUL AS BETA 3-ADRENORECEPTOR AGONISTS AND ANTAGONISTS OF THE BETA 1 AND BETA 2-ADRENORECEPTORS AND PHARMACEUTICAL COMPOSITION THEREOF SMITHKLINE BEECHAM PLC (GB) 1997-05-14 EP disclosed
WO-1996004233-A1 ARYLOXY AND ARYLTHIOPROPANOLAMINE DERIVATIVES USEFUL AS BETA 3-ADRENORECEPTOR AGONISTS AND ANTAGONISTS OF THE BETA 1 AND BETA 2-ADRENORECEPTORS AND PHARMACEUTICAL COMPOSITION THEREOF SMITHKLINE BEECHAM PLC (GB) 1996-02-15 WO disclosed